NewCo News: Making Cancer Feel the 'Heat' Via Immune-Targeted Vaccine
By Jennifer Boggs
Friday, July 15, 2011
A half-dozen biotechs are in the clinic with heat-shock protein (Hsp)-based drugs, but 2008 start-up Heat Biologics is putting a twist on that approach by developing Hsp vaccines capable of inducing and maintaining immune responses against cancer and other diseases.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.